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Abstract: The consumption of new psychoactive substances (NPSs) has been increasing, and this
problem affects several countries worldwide. There is a class of NPSs of natural origin, consisting of
plants and fungi, which have a wide range of alkaloids, responsible for causing relaxing, stimulat-
ing or hallucinogenic effects. The consumption of some of these substances is prompted by religious
beliefs and cultural reasons, making the legislation very variable or even ambiguous. However,
the abusive consumption of these substances can present an enormous risk to the health of the individ-
uals, since their metabolism and effects are not yet fully known. Additionally, NPSs are widely spread
over the internet, and their appearance is very fast, which requires the development of sophisticated
analytical methodologies, capable of detecting these compounds. Thus, the objective of this work is
to review the toxicological aspects, traditional use/therapeutic potential and the analytical methods
developed in biological matrices in twelve plant specimens (Areca catechu, Argyreia nervosa, Ayahuasca,
Catha edulis, Datura stramonium, Lophophora williamsii, Mandragora officinarum, Mitragyna speciosa,
Piper methysticum Forst, Psilocybe, Salvia divinorum and Tabernanthe iboga).
Keywords: NPS of natural origin; psychoactive effects; toxicological aspects; traditional uses; analyt-
ical methodologies
1. Introduction
The use of drugs of abuse is a concern that has been increasing over the years.
About 96 million individuals have already used drugs of abuse in the European Union,
cannabis being the most used (27.4%), followed by cocaine (5.4%) and then ecstasy (4.1%)
and amphetamines (3.7%) [1]. In recent years, a trend of new psychoactive substance (NPS)
consumption has been reported. The European Monitoring Center for Drugs and Drug
Addiction (EMCDDA) defines those compounds as “a new narcotic or psychotropic drug,
in pure form or in preparation, that is not controlled by the United Nations Drug Conven-
tions, but which may pose a public health threat comparable to that posed by substances
listed in these conventions” [2]. NPSs have spread around the world, mainly because they
are marketed on the internet in dark web forums, with different names, namely “bath salts”,
“legal highs”, or “research chemicals” [3]. These substances are generally consumed be-
cause they are able to mimic the effects of more conventional drugs of abuse and because
they are not detected in common screening methods [4–6]. However, the various risks
associated with the consumption of NPSs are described in the literature, as well as the
resulting health problems [7–9].
Despite the term “new” referring to a recent appearance, the truth is that some of these
compounds have existed for decades, but they only became available on the market more
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recently, and consequently, their commercialization is not yet regulated [3]. The constant
appearance of these drugs (about 50 new per year) is a concern in terms of controlling their
marketing [1]. Additionally, considering the health hazard presented by NPSs, the United
Nations Office on Drugs and Crime (UNODC) and the EMCDDA have implemented early
warning systems in order to detect these compounds [10,11].
NPSs may have a synthetic or natural origin, the most recognized synthetic NPS
being synthetic cannabinoids, cathinones and opioids, piperazines, phenethylamines, de-
signer benzodiazepines, indoalkylamines and arylcyclohexylamines [2–4]. NPSs of natural
origin consist mainly of alkaloids naturally present in plants that, when consumed, al-
low the user to experience new sensations and different “mental states” [3,12]. These plants
come mainly from South America and Asia but also from Africa and Russia [3] and, depend-
ing on their constituents, can trigger relaxing and/or sedative effects, such as Areca catechu
(A. catechu) and Mitragyna speciosa (M. speciosa), hallucinogenic effects, as the constituents
of Ayahuasca, or stimulating effects, such as Catha edulis (C. edulis) [3,13]. The consumption
of preparations containing alkaloids of natural origin is often prompted by religious beliefs
or cultural reasons, making it difficult to estimate the worldwide consumption of these
substances [3]. For these reasons, the legislation that regulates these substances is quite
variable and may even be ambiguous [2].
The metabolism of these substances is not fully studied, and therefore the resulting
metabolites and their potential concentrations are not known [2,3]. Another gap that
needs further study is the acute toxicity of many of these substances, which are also not
completely known [2]. In fact, the symptoms described during intoxication with an NPS
are confused with symptoms of consumption of other substances, namely medicines [2].
Thus, developing analytical methodologies is greatly important for the detection and
quantification of potentially dangerous compounds present in these natural products.
However, most developed analytical methods have focused on the detection of alkaloids
naturally present in plant materials [14].
In this review, we sought to address the toxicological aspects of several psychoactive
substances present in different plants, as well as some therapeutic properties/traditional
uses. In addition, the analytical methods developed in biological samples aimed at the
detection of psychoactive substances from the same plants were also discussed.
2. Areca catechu (Betel Quid)
Currently, A. catechu (Figure 1A) is distributed in Africa, Europe and America, in spite
of its main origin being Asia (Sri Lanka and Malaysia) [2]. The areca nut is the fruit
produced by this plant, having been consumed for centuries as a traditional remedy or
in rituals [15]. This fruit is normally chewed and can be consumed together with other
substances in the form of a “betel quid” [15,16]. Areca nut is the fourth drug with the high-
est consumption rate worldwide, possibly due to its stimulating, relaxing or aphrodisiac
effects [15,16]. Arecoline (Figure 1B) is the main psychoactive compound present in the
fruit of A. catechu [2]. This compound is an alkaloid that works as a competitive inhibitor
of gamma-aminobutyric acid (GABA) and as a non-selective nicotinic and muscarinic
agonist [3,17,18]. Once in the body, arecoline quickly crosses the blood-brain barrier, exert-
ing effects on the parasympathetic nervous system [3]. However, this fruit is addictive and
can cause several adverse effects, namely on the digestive system and abstinence syndrome
(insomnia, mood swings, irritability and anxiety) [3,15]. Other effects, such as severe
extrapyramidal syndrome, asthma and myocardial infarction, have also been associated
with the consumption of this fruit [19,20]. However, the use of this fruit for medicinal
purposes has also been described, since antiquity, by Hindu and Buddhist peoples [21].
The consumption of areca nut has been associated with general properties such as satisfac-
tion, well-being, psychostimulating effects, stress reduction, gum strengthening and breath
sweetening [21]. Additionally, this fruit is used in the treatment of malaria, fever, hernia,
hypertension, urinary stones and in the manufacture of formulations for the treatment
of digestive diseases, diarrhea and indigestion [21]. Studies have also indicated that the
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consumption of areca nut is associated with antimicrobial [22,23], cardiovascular [23,24]
and digestive effects [21,23–25]. In addition to the A. catechu fruit, roots and leaves were
also traditionally used in medicine [21].
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Figure 1. A. catechu (A) and the main compound arecoline (B).
A. catechu and its fruit are not controlled substances, and therefore there is no legisla-
tion for their consumption in the United States of America and in the European Union [3].
Thus, several analytical methods, which allow the measur ment of th se substances,
have been developed (Table 1). Conventional samples, such as blood, continue to be used
for the detection of the most diverse compounds, including a ecoli e [26]. Wu et al. [26] de-
veloped an analytical method where they proceed to quantify arecoline in an LC-MS/MS
equipment, using 1 mL of blood, obtaining a limit of detection (LOD) of 0.02 ng/mL and
a limit of quantification (LOQ) of 0.5 ng/mL. Urine is another biological matrix that has
been used for the measurement of arecoline [27]. Pichini et al. [27] developed an analytical
method in HPLC-MS equipment, where they used 1 mL of urine, having managed to
quantify arecoline. In the same study, it was also possible to quantify the same compound
in samples of meconium (1 g) and cord serum (1 mL) [27]. However, other alternative
samples, such as teeth [28], saliva [29,30] and breast milk [31] have been also used in
the development of new analytical methods for detecting arecoline. Pellegrini et al. [31]
developed a method for the determination of arecoline in LC-MS/MS, using 1 mL of breast
milk. This method had a LOD of 16 ng/mg and LOQ of 50 ng/mg [31].
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3. Argyreia nervosa (Adhoguda)
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Africa and subtropical America [33]. This plant, also known as Adhoguda, Vidhara,
Elephant Creeper, Rivea corymbosa, Hawaiian Baby Woodrose or Morning Glory or
Ipomoea violacea, possesses psychoactive alkaloids in its seeds [3]. Isoergine (Figure 2B) and
lysergamide (LSA) (Figure 2C) are the compounds responsible for the hallucinogenic prop-
erties of this plant, being able to induce effects similar to lysergic acid diethylamide (LSD),
albeit with a lower intensity [34]. A. nervosa seeds have a total of ergoline alkaloids between
0.5% and 0.9%, of which 0.19% correspond to isoergine and 0.14% correspond to LSA [35].
The LSA exerts its effects by binding to dopamine D2 receptors and consequent inhibition
of adenylate cyclase and reduction in the production of cyclic adenosine monophosphate
(cAMP) [36]. The consumption of this plant for medicinal purposes has also been described,
namely as a diuretic and aphrodisiac [13]. Analgesic, anti-inflammatory, immunomod-
ulatory, hepatoprotective and hypoglycemic properties have also been described [13,37].
A. nervosa roots are also used in the treatment of diseases of the central nervous system,
rheumatism, gonorrhea and chronic ulcer. On the other hand, antimicrobial activity has
been associated with the plant leaf [13,37]. In addition to the two alkaloids already men-
tioned, others have been also isolated from plants, namely erginine, ergometrine, lysergol,
peniclavine, chanoclavin I, chanoclavin II, ergometrinine, elimoclavin and egine, but their
effects are not yet known [38].
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several studies that report therapeutic properties. Recently their proprieties were re-
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Figure 2. Argyreia nervosa (A) and the m in compounds isoergine (B) and lysergamide (LSA) (C).
LSA is a controlled substance in some European countries, namely in the United
Kingdom and Italy. It is also controlled in the United States of America, but the plant and
its seeds are freely sold [3]. There are currently analytical methodologies developed that
allow quantifying the LSA. Paulke et al. [39] developed an analytical method, with 1 mL
of serum and urine, to detect and quantify LSA. The analytes were extracted using the
SPE (solid-phase extraction) technique and quantified on HPLC-FLD equipme t [39].
The method had detection nd quantificati n limits of 0.05–0.15 ng/mL and 0.17 ng/mL,
respectively, and recoveries between 69.4% and 78.8% [39].
4. Ayahuasca (“Hoasca”)
Ayahuasca is a word of Quechua origin, compos d of two terms: “aya” and “waska”,
which mean “spi it” and “vine”, respecti ly [40]. On its whole, the word Ay huasca means
“rope of the soul”, and it is also known as caapi, daime, hoasca, yagé and nate a [3,40].
This term refers to a psychoactive drink, traditional in South America (Figure 3A). More re-
cently, it has been imported into some countries in Europe and Asia [3,41,42]. Ayahuasca con-
sists of a brown, thick and oily liquid, the result of a decoction of shavings from the ste
of Banisteriopsis caapi (B. caapi) and leaves of Psychotria viridis (P. viridis) (Figure 3B) [41,42].
Additionally, other species of natural origin, which replace those already mentioned, can be
used in the preparation of Ayahuasca, namely Brugmansia suaveolens, Psychotria carthagenen-
sis, Nicotiana tabacum, Tabernaemontana spp., Brunfelsia spp., Datura suaveolens, Iochroma fuch-
sioides, Malouetia tamarquina, Juanulloa spp. and Peganum harmala, among other products
with hallucinogenic compounds [43].
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Figure 3. Ayahuasca decoction (A); Banisteriopsis caapi stem shavings and Psychotria viridis leaves
i the preparation of the Ayahuasca beverage (B); main compounds present in Ayahu sca:
The effects of this psychoactive mixture are due to the synergy potential of N,N-
dimethyltryptamine (DMT) (Figure 3C), a hallucinogenic compound from P. viridis, and of
the harmine (Figure 3D), harmaline (Figure 3E) and tetrahydroharmine (THH) (Figure 3F),
which are β-carbolinic alkaloids present in B. caapi [44,45]. DMT is a tryptamine that
acts as an agonist for serotonin receptors (5-HT1A/2A/2C) [3]. When this compound is
ingested alone, it undergoes metabolism by peripheral monoamine oxidase A (MAO-A),
being inactive [46]. However, when DMT is ingested together with β-carbolinic alkaloids,
it is able to penetrate the central nervous system, since it temporarily inhibits MAO-
A [44,46–48]. In addition, THH also inhibits serotonin reuptake by increasing the effects
of DMT [49]. Users describe visual hallucinations, with effects on temperature, pupil size
and changes in the endocrine, cardiovascular and immune systems [3,50]. Side effects
such as mydriasis, vomiting, hypertension, tachycardia, agitation, paranoia, anxiety and
depression have also been described [3,50,51]. However, there are several studies that
report therapeutic properties. Recently their proprieties were reported as antimicrobial
and antioxidant agents [52], as well as their effect over dopaminergic neuron cells [53].
Studies have shown that a single dose of Ayahuasca leads to a rapid reduction in depressive
symptoms, and this reduction is maintained for three weeks [54,55]. Other studies show
that the consumption of this decoction results in a significant reduction in anxiety and
panic [54,56]. The reduction of drug and alcohol abuse [57–59], attention problems [60]
and decreased physical pain, fatigue, insomnia, irritability and obsession [61] have also
been described.
Ayahuasca has been used in religious rituals in the Amazon for centuries, and more
recently by religious entities such as União do Vegetal (UDV) and Santo Daime [3,40].
DMT-containing substances are controlled in the United States of America and in some
European countries [3]. However, the consumption of P. viridis and B. caapi is not controlled,
and the use of Ayahuasca for religious purposes is legal in the United States of America and
Brazil [3]. There are currently several analytical methodologies that allow the detection and
quantification of the compounds from Ayahuasca and its metabolites (Table 2). The samples
of choice for the quantification of these compounds are the so-called conventional samples,
namely blood [62], plasma [63,64] and urine [65,66]. Yritia et al. [63] and Oliveira et al. [64]
developed analytical methods for the detection of DMT and β-carbolines, using 1 mL of
plasma. Both methods used SPE [63,64] as a sample pre-treatment technique, and in the first
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study, a liquid-liquid extraction (LLE) was also performed [63]. Both studies showed good
limits of detection and quantification, as well as good recoveries [63,64]. More recently,
Pichini et al. [67] carried out a study, where they quantified DMT, using only 25 mg of
hair. The hair sample was initially hydrolyzed with an M3 reagent, and HPLC-MS-MS
equipment was used to quantify the analyte [67]. The LOD varied between 0.01 ng/mg and
0.02 ng/mg and the LOQ between 0.03 ng/mg and 0.05 ng/mg, with recoveries between
76.6% and 97.4% [67].
Table 2. Analytical methods for the determination of the main components of Ayahuasca.
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5. Catha edulis (Khat)
C. edulis (Figure 4A) comes from some West African countries, as well as from Yemen,
Ethiopia and the Arabian Peninsula [2]. This plant is often used as a drug of abuse since
it allows to mimic the effects of synthetic cathinones but with a lower risk of intoxica-
tion, with no record of deaths associated with its consumption [2]. C. edulis is also called
khat, qat and kafta, among others, and it is usually consumed in smoked form or by
chewing fresh leaves [3]. The psychoactive components present in the leaves of this plant
are S-(−)-cathinone (Figure 4B), cathine ([S,S-(+)-norpseudoephedrine]) (Figure 4C) and
phenylpropanolamine (Figure 4D). S-(−)-cathinone is photosensitive, and therefore it de-
grades easily with sun exposure, being the major compound in fresh khat leaves, but it is
not found in older leaves [68]. After sun exposure, S-(−)-cathinone degrades into chatine
and (−)-norephedrine, these being the compounds present mostly in the older leaves [68].
When consuming khat, the active compounds degrade not only into chatine and (−)-
norephedrine but also into [R,S-(−)-norephedrine] and [R,R-(−)-norpseudoephedrine],
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compounds structurally similar to amphetamine [69]. Consumers of this plant describe
effects such as hyperthermia, euphoria, increased breathing and sensory stimulation, ex-
citation and anorexia. However, adverse effects such as violent behavior, schizophrenia,
paranoia and psychosis, increased blood pressure, insomnia, tachycardia, irritability, mi-
graine and sexual dysfunction have also been described [3].
The consumption and trade of khat leaves are not regulated by any international
system, but the consumption and trade of cathinone and cathine are prohibited world-
wide [3]. In some countries, khat is considered a controlled substance, namely Ireland,
France, Germany, Denmark and the United States of America. In the Netherlands, its trade
is not prohibited, but is restricted and, in Canada, the possession of khat is allowed, but its
import and trade are also illegal [3]. On the other hand, countries like Yemen, Somalia and
Ethiopia allow the consumption of khat, since it is a cultural habit [3].
There are currently analytical methodologies developed that allow quantifying the
compounds present in khat (Table 3). Sørensen [70] developed an analytical method to
quantify 15 compounds, using LC-MS/MS equipment with only 300 µL of blood. The sam-
ple was treated with methanol to precipitate proteins, and then it was filtered [70]. The an-
alytical method showed recoveries between 87% and 106% and a LOD between 0.5 ng/mL
and 3 ng/mL [70]. In addition, samples such as plasma [71], urine [72] and oral fluid [73]
were used to quantify these compounds. Mohamed et al. [73] used 500 µL of oral fluid
to quantify cathine, methcathinone, cathinone and ephedrine. The samples were submit-
ted to an LLE (ethyl acetate) extraction technique and subsequently analyzed by GC-MS.
The analytical method showed a LOQ of 20 ng/mL and a LOD of 10 ng/mL [73].

















GC-MS (EI) 10.0 μg/L 20.0 μg/L - [73] 
Caption: EI (electron impact); ESI (electrospray ionization); GC (gas chromatography); LC (liquid chromatography); LLE 
(liquid-liquid extraction); MS (mass spectrometry); MS/MS (tandem mass spectrometry); PP (protein precipitation); SPE 
(solid-phase extraction). 
 
Figure 4. C. edulis (A) and the main compounds S-(−)-cathinone (B), cathine 
([S,S-(+)-norpseudoephedrine]) (C) and phenylpropanolamine (D). 
6. Datura stramonium (Jimson Weed) 
D. stramonium (Figure 5A), originally from the United States of America, consists of a 
seasonal herb that grows naturally [2]. This species, also known as Jimson Weed, was 
traditionally used by the Pueblo Indians, due to its analgesic properties [76]. Moreover, in 
Western medicine, Jimson Weed was used to treat asthma [76]. This plant is usually 
consumed by eating its seeds or flowers intact, or in the form of an infusion of leaves or 
crushed seeds [77,78]. Dried leaves, flowers and seeds are also consumed in a smoked 
form, and there is also Asthmador™ powder available for consumption in smoked form 
or by inhalation [78,79]. The consumption of D. stramonium also causes hallucinogenic 
effects, which are due to the presence of the alkaloids scopolamine (Figure 5B) and atro-
pine (Figure 5C) distributed throughout the plant [2]. These compounds are tertiary 
amines and therefore cross the blood-brain barrier rapidly [79]. Scopolamine acts at the 
level of the central nervous system, exerting antimuscarinic effects [80]. The effects of 
Jimson Weed consumption include tachypnea, delirium, psychomotor agitation, dilation 
of the pupils, blurred vision or photophobia [78,79,81]. Other effects, such as peripheral 
vasodilation, decreased thermoregulation, vomiting, constipation and difficulties in uri-
nating, have been also described [76,82]. At higher doses, respiratory depression and 
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6. Datura stramonium (Jimson Weed)
D. stramonium (Figure 5A), originally from the United States of America, consists of a
seasonal herb that grows naturally [2]. This species, also known as Jimson Weed, was tra-
ditionally used by the Pueblo Indians, due to its analgesic properties [76]. Moreover,
in Western medicine, Jimson Weed was used to treat asthma [76]. This plant is usually
consumed by eating its seeds or flowers intact, or in the form of an infusion of leaves or
crushed seeds [77,78]. Dried leaves, flowers and seeds are also consumed in a smoked
form, and there is also Asthmador™ powder available for consumption in smoked form
or by inhalation [78,79]. The consumption of D. stramonium also causes hallucinogenic
effects, which are due to the presence of the alkaloids scopolamine (Figure 5B) and atropine
(Figure 5C) distributed throughout the plant [2]. These compounds are tertiary amines and
therefore cross the blood-brain barrier rapidly [79]. Scopolamine acts at the level of the
central nervous system, exerting antimuscarinic effects [80]. The effects of Jimson Weed
consumption include tachypnea, delirium, psychomotor agitation, dilation of the pupils,
blurred vision or photophobia [78,79,81]. Other effects, such as peripheral vasodilation,
decreased thermoregulation, vomiting, constipation and difficulties in urinating, have been
also described [76,82]. At higher doses, respiratory depression and even cardiac arrest,
seizures or hypoventilation may occur [79]. Some analytical methods have been developed
to quantify the alkaloids scopolamine and atropine (Table 4). These are discussed below.
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scopolamine (Figure 6D), responsible for its healing, hallucinogenic and poisonous prop-
erties [83,84]. Since ancient times, mandrake was used as a surgical anesthetic in Rome
and Greece [85]. It is also believed that this plant has aphrodisiac properties and its fruit
increases fertility [85].
The consumption of mandrake can compromise the autonomic nervous system, re-
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8. Lophophora williamsii (Peyote) 
L. williamsii (Figure 7A), also known as Peyote, is a cactus from northern Mexico and 
the United States of America [92,93]. This plant was traditionally eaten in religious ritu-
als, by indigenous peoples in the countries already mentioned [50]. Normally, the flesh of 
the fresh cactus is ingested, and it can also be dried and subsequently ingested or used to 
make teas [92,94]. L. williamsii contains a compound called mescaline 
[2-(3,4,5-trimethylphenyl) ethanamine] (Figure 7B), a member of the phenylalkylamine 
class, responsible for the hallucinogenic properties of the plant [79,95]. This compound is 
also found for sale in the form of powder, which can be inflated or ingested orally [79]. 
Once consumed, mescaline accesses the central nervous system, acting at the level of 
serotonergic receptors 5-HT2 as an agonist of subtypes 5-HT2a, 5-HT2b and 5-HT2c [95]. 
The effects when consuming this plant include paranoia, compulsion, paresthesia, 
changes in color perception, headaches, mydriasis, spasms and psychomotor agitation 
[93,96,97]. Other effects at the cardiovascular, gastrointestinal and renal levels have been 
also described, namely hypertension and tachycardia, vomiting and decreased filtration 
rate at the glomerular level [93,98,99]. However, beneficial effects have been also de-
scribed. One study demonstrated that L. williamsii extracts were effective in treating 
rheumatism, wounds, burns and snakebites [100]. Another study showed that this plant 
has antimicrobial properties against Staphylococcus aureus [100] Additionally, L. williamsii 
is used by some tribes to treat fever, labor pain, toothache, diabetes, blindness, breast 
pain and skin diseases [100]. 
Currently, substances containing mescaline are included in Annex I of the 1967 
United Nations Convention on Drugs [100]. Given the effects of this plant, it is crucial to 
develop new analytical methodologies to detect mescaline and its metabolites in biolog-
ical samples. Until now, methodologies have been developed using chromatography, 
namely in alternative samples such as hair [67]. Pichini et al. [67] developed an analytical 
method, using UHPLC-MS/MS equipment, to quantify several naturally occurring hal-
lucinogens, including mescaline. For this purpose, 25 mg of hair was hydrolyzed with an 
M3 reagent. The method presented LOD values between 0.01 ng/mg and 0.02 ng/mg, 
re 6. M. officinarum (A) and the main compounds hyoscyamine (B), atropine (C) and scopo-
lamine (D).
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There are currently analytical methodologies developed with different biological sam-
ples, which allow the quantification of atropine and scopolamine (Table 4). Pietsch et al. [88]
developed an analytical method with 1 mL of serum and urine to detect and quan-
tify 13 compounds, namely scopolamine and atropine. The analytes were extracted us-
ing the SPE technique and quantified using HPLC-PDA and HPLC-UV equipment [88].
The method presented quantification limits of 0.3–94 ng/mL and recoveries between
23.7% and 86.9% [88]. In addition, Carlier et al. [89] quantified atropine and scopolamine,
among other compounds, in a single analytical method. The SPE technique was used
as a pre-treatment of the blood sample (1 mL), having subsequently been quantified in
UHPLC-MS/MS equipment [89]. The method had a LOQ of 10 ng/mL and detection limits
between 0.1 and 1.6 ng/mL [89].
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8. Lophophora williamsii (Peyote)
L. williamsii (Figure 7A), also known as Peyote, is a cactus from northern Mexico and
the United States of America [92,93]. This plant was traditionally eaten in religious rituals,
by indigenous peoples in the countries already mentioned [50]. Normally, the flesh of the
fresh cactus is ingested, and it can also be dried and subsequently ingested or used to make
teas [92,94]. L. williamsii contains a compound called mescaline [2-(3,4,5-trimethylphenyl)
ethanamine] (Figure 7B), a member of the phenylalkylamine class, responsible for the
hallucinogenic properties of the plant [79,95]. This compound is also found for sale
in the form of powder, which can be inflated or ingested orally [79]. Once consumed,
mescaline accesses the central nervous system, acting at the level of serotonergic receptors
5-HT2 as an agonist of subtypes 5-HT2a, 5-HT2b and 5-HT2c [95].
The effects when consuming this plant include paranoia, compulsion, paresthe-
sia, changes in color perception, headaches, mydriasis, spasms and psychomotor agi-
tation [93,96,97]. Other effects at the cardiovascular, gastrointestinal and renal levels have
been also described, namely hypertension and tachycardia, vomiting and decreased fil-
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tration rate at the glomerular level [93,98,99]. However, beneficial effects have been also
described. One study demonstrated that L. williamsii extracts were effective in treating
rheumatism, wounds, burns and snakebites [100]. Another study showed that this plant
has antimicrobial properties against Staphylococcus aureus [100] Additionally, L. williamsii is
used by some tribes to treat fever, labor pain, toothache, diabetes, blindness, breast pain
and skin diseases [100].
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graphic location [3,111]. The most abundant psychoactive compound is mitragynine 
(Figure 8B), corresponding to a total of 66.2% of the alkaloids content. However, the 
abundance of this compound in Malaysian plants was only 10% [12]. Other alkaloids 
with pharmacological activity were also detected, such as 7-hydroxmitraginine (Figure 
8C) and corinantheidine [110–114]. In addition, other alkaloids have been discovered that 
may contribute to pharmacological effects, namely corinantheidine, specioginine and 
paynantheine [3]. The alkaloids present in M. speciosa show high lipophilicity, crossing 
the blood-brain barrier, and a high affinity for opioid receptors [3]. Thus, 
7-hydroxmitraginin binds to the supraspinous k-opioid and µ-opioid receptors, exerting 
their effects [3]. In addition to these, mitragynine binds to δ-opioid receptors, thereby 
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Figure 7. Lophophora williamsii (A) and the main compound mescaline (B).
Currently, substances containing mescaline are included in Annex I of the 1967 United
Nations Convention on Drugs [100]. Given the effects of this plant, it is crucial to develop
new analytical methodologies to detect mescaline and its metabolites in biological sam-
ples. Until now, methodologies have been developed using chromatography, namely in
alternative samples such as hair [67]. Pichini et al. [67] developed an analytical method,
using UHPLC-MS/MS equipment, to quantify several naturally occurring hallucinogens,
including mescaline. For this purpose, 25 mg of hair was hydrolyzed with an M3 reagent.
The method presented LOD values between 0.01 ng/mg and 0.02 ng/mg, LOQ between
0.03 ng/mg and 0.05 ng/mg and recoveries between 79.6% and 97.4% [67]. Another study
by Beyer et al. [71] also allowed to quantify mescaline, using LC-MS/MS equipment with
1 mL of plasma, pre-treated with the SPE technique.
9. Mitragyna speciosa (Kratom)
M. speciosa (Figure 8A), also known as Kratom, appeared on the Asian continent,
namely in countries like Biak, Malaysia and Thailand [2]. Currently, this plant is distributed
in several regions of the world [3,12]. M. speciosa has been used for several years by rural
workers and peasants in Asian people for reducing fatigue and increasing productivity at
work, coughing, pain, fever, diarrhea, hypertension and diabetes. More recently, it began to
be consumed in a recreational context in Europe and the United States of America [101–109].
Kratom leaves have been also used as a substitute for opium, as well as in morphine
withdrawal treatments [12,50]. The preferred mode of consumption is chewing fresh
leaves, but dried leaves can also be eaten or smoked [3,50]. Other forms of consumption
of this plant include the preparation of teas and pastes by boiling the leaves for a long
period [16]. Currently, there is greater ease in the consumption of this plant, since capsules,
powders and drinks ar available that can be easily purchased [3,110].
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10. Piper Methysticum Forst (Kava) 
Some parts of P. methtysticum (Figure 9A) (roots and stems) are used in the manu-
facture of Kava, a psychotropic drink from the Pacific region [2]. Kava was consumed 
due to its therapeutic properties, namely in reducing fatigue and anxiety, relieving pain 
or inducing sleep [125]. Other treatments such as restlessness and anxiety were also as-
sociated with the consumption of Kava [3]. However, the use of this substance is associ-
ated with hepatotoxicity [125]. The effects of Kava are due to kavalactones, namely ka-
vain (Figure 9B), yangonin (Figure 9C), desmethoxy-iangonin, 7,8-dihydrokavain, me-
thysticin and 7,8-dihydromethysticin, to the derivatives of cinnamic acid, flavanones and 
chalcones [2]. These compounds act at the level of the central nervous system, inhibiting 
monoamine oxidase B, recapturing of noradrenaline and dopamine and interacting with 
γ-amino butyric acid [126]. 
The sale of P. methysticum is controlled in Holland, Switzerland and France, and its 
sale and import are prohibited in the United Kingdom. In Poland, sales for human con-
sumption are also prohibited. However, in most countries, this substance remains legal 
[3]. Thus, the development of analytical methods for the detection of these compounds is 
becoming increasingly important (Table 6). Villain et al. [127] developed a method for the 
determination of kavain in GC-MS/MS, using between 29 and 50 mg of hair. The method 
had a LOD of 30 ng/g and a LOQ of 100 ng/g [127]. Another more recent study, carried 
out by Tarbah et al. [128], allowed to quantify 10 compounds, using between 21 and 253 
mg of hair. The sample was initially decontaminated, then digested, using three different 
types of equipment for quantification: HPLC-DAD, LC-MS/MS and GC/TOF-MS [128]. 
  
Figure 8. M. speciosa (A) and the main compounds mitragynine (B) and 7-hydroxymitragynine (C).
Kratom has psychoactive properties, which are due to the presence of about 40 al-
kaloids in the plant [3,50]. These compounds correspond to about 0.5%–1.5% of the
compounds and their concentrations vary with the harvesting season, age and geographic
location [3,111]. The most abundant psychoactive compound is mitragynine (Figure 8B),
corresponding to a total of 66.2% of the alkaloids content. However, the abundance of this
compound in Malaysian plants was only 10% [12]. Other alkaloids with pharmacological
activity were also detected, such as 7-hydroxmitraginine (Figure 8C) and corinanthei-
dine [110–114]. In addition, other alkaloids have been discovered that may contribute
to pharmacological effects, namely corinantheidine, specioginine and paynantheine [3].
The alkaloids present in M. speciosa show high lipophilicity, crossing the blood-brain bar-
rier, and a high affinity for opioid receptors [3]. Thus, 7-hydroxmitraginin binds to the
supraspinous k-opioid and µ-opioid receptors, exerting their effects [3]. In addition to these,
mitragynine binds to δ-opioid receptors, thereby exercising analgesic effects [3,50]. Mitrag-
ynine is abl t block Ca2+ channels, affecting the release of n urotransmitters [115,116].
Thus, antidepressant, antioxidant and anti-inflammatory properties have been associated
with kratom con umption [117,118]. The use of this s bstance for titution tre tment in
chronic opioid us rs has als been reported [3,50].
Adverse ffects when consuming this plant include withdrawal and n onatal with-
rawal syndrome, seizures, weight loss, dehydration, fatigue, insomnia, constipation an
yperpigmentatio [50,103,105,119,120]. However, M. speciosa is not on the United N tions
Drug Convention Schedule [3]. These compounds are controlled in the United States
of Amer ca, New Zealand, Australia, Myan ar, Thailand, Malaysia a d in some Euro-
pean countries [3].
Thus, it is crucial to develop analytical methods to detect and quantify the com-
pounds present in M. speciosa (Table 5). Carlier et al. [89] developed an analytical method
where they used 1 mL of blood to detect mitragynine (among other compounds), us-
ing UHPLC-MS/MS equipment. Lee et al. [121] developed an analytical method in LC-
MS/MS, where they used SPE and enzymatic hydrolysis as a method of pre-treatment
of the urine sample, to quantify 16-carboxy mitragynine, 9-O-demethyl mitragynine and
mitragynine. More recently, Basiliere et al. [122] developed an analytical method using
LC-Q/TOF-MS equipment for the quantification of mitragynine, 7-hydroxymitragynine,
among other compounds. One milliliter of urine, pre-treated with SPE, was used, obtain-
ing a LOD of 0.25–1 ng/mL and a LOQ of 0.5–1 ng/mL [122].
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Table 5. Analytical methods for the determination of the main components of Mitragyna speciosa.
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10. Piper methysticum Forst (Kava)
Some parts of P. methtysticum (Figure 9A) (roots and stems) are used in the manufacture
of Kava, a psychotropic drink from the Pacific region [2]. Kava was consumed due to its
therapeutic properties, namely in reducing fatigue and anxiety, relieving pain or inducing
sleep [125]. Other treatments such as restlessness and anxiety were also associated with
the consumption of Kava [3]. However, the use of this substance is associated with
hepatotoxicity [125]. The effects of Kava are due to kavalactones, namely kavain (Figure 9B),
yangonin (Figure 9C), desmethoxy-iangonin, 7,8-dihydrokavain, methysticin and 7,8-
dihydromethysticin, to the derivatives of cinnamic acid, flavanones and chalcones [2].
These compounds act at the level of the central nervous system, inhibiting monoamine
oxidase B, recapturing of noradrenaline and dopamine and interacting with γ-amino
butyric acid [126].




Figure 9. P. methysticum (A) and the main compounds kavain (B) and yangonin (C). 
11. Psilocybe genus (Magic mushrooms) 
Psilocybe (Figure 10A) is a genus of hallucinogenic fungi, commonly known as magic 
mushrooms [131]. These specimens originate from certain regions of South America, but 
it is also possible to find them in Western Europe and in the United States of America 
[79,92]. The magic mushrooms were initially used in religious rituals, by the Aztec people 
in Mexico, persisting until today [50,79]. The active compounds present in these fungi are 
psilocybin (Figure 10B) and psilocin (Figure 10C), which consist of a substituted in-
dolealkylamine [3,79]. There are about 190 species of mushrooms of the genus Psilocybe, 
which contain these two compounds responsible for the psychoactive effects of these 
fungi [131]. Mushrooms can be eaten after drying and making tea, but the most common 
route of consumption is by eating whole mushroom capsules [92]. After being consumed, 
psilocybin is converted into psilocin, and it acts as an agonist for the serotonergic recep-
tors 5-HT1a and 5-HT2a, exerting its psychoactive effects [79]. In addition, these com-
pounds can also increase the release of glutamate, which activates receptors such as 
N-methyl-d-aspartic acid receptors and 
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors [50,132]. The effects 
caused when consuming magic mushrooms can also be partially and indirectly mediated 
by dopamine [133]. 
The effects of Psilocybe consumption include changes in perception similar to drugs 
such as LSD, namely changes in visual and auditory perception [3]. Mystical experiences, 
tachycardia, headache, sweating, mydriasis, chills, nausea and increased body tempera-
ture are also associated with the consumption of magic mushrooms [134,135]. Other ef-
fects reported when consuming these substances are paranoia, dizziness and imbalance 
and abdominal pain, [79,135]. Moreover, it has been reported that psilocybin can be used 
to treat anxiety and resistant depression [136]. 
Psilocybe mushrooms are illegal all over the world [137]. However, in some coun-
tries, the law is not consensual, namely in the Netherlands where the mushroom is ille-
gal, but the Sclerotia truffle (philosopher’s stone) is not [3]. Given the worldwide con-
sumption of this substance, the development of new analytical methods that allow the 
determination of these compounds is crucial (Table 7). Several samples were used to 
quantify the active compounds of Psilocybe, namely urine [91,138], serum [139] and hair 
[67]. Kamata et al. [139] developed a method for the quantification of psilocin glucu-
ronide, where they used only 100 µL of serum. The sample was subjected to an enzymatic 
hydrolysis and deproteinization process, after which it was injected into LC-MS and 
LC-MS/MS equipment. The method showed 0.5 ng/mL LOD. The same authors had pre-
Figure 9. P. methysticum (A) and the ain co pounds kavain ( ) an yangonin ( ).
The sale of P. methysticum is controlled in Holland, Switzerland and France, and its
sale and import are prohibited in the United Kingdom. In Poland, sales for human con-
sumption are also prohibited. However, in most countries, this substance remains legal [3].
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Thus, the development of analytical methods for the detection of these compounds is
becoming increasingly important (Table 6). Villain et al. [127] developed a method for the
determination of kavain in GC-MS/MS, using between 29 and 50 mg of hair. The method
had a LOD of 30 ng/g and a LOQ of 100 ng/g [127]. Another more recent study, carried out
by Tarbah et al. [128], allowed to quantify 10 compounds, using between 21 and 253 mg of
hair. The sample was initially decontaminated, then digested, using three different types of
equipment for quantification: HPLC-DAD, LC-MS/MS and GC/TOF-MS [128].
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Caption: DAD (diode array detector); EI (electron impact); ESI (electrospray ionization); GC (gas chromatography); HESI (heated elec-
trospray); HPLC (high performance liquid chromatography); LC (liquid chromatography); LLE (liquid-liquid extraction); MS (mass
spectrometry); MS/MS (tandem mass spectrometry); PP (protein precipitation); SPE (solid-phase extraction); ToF (time of flight); UH-
PLC (ultrahigh-performance liquid chromatography).
11. Psilocybe Genus (Magic Mushrooms)
Psilocybe (Figure 10A) is a genus of hallucinogenic fungi, commonly known as magic
mushrooms [131]. These specimens originate from certain regions of South America, but it
is also possible to find them in Western Europe and in the United States of America [79,92].
The magic mushrooms were initially used in religious rituals, by the Aztec people in
Mexico, persisting until today [50,79]. The active compounds present in these fungi are
psilocybin (Figure 10B) and psilocin (Figure 10C), which consist of a substituted indolealky-
lamine [3,79]. There are about 190 species of mushrooms of the genus Psilocybe, which con-
tain these two compounds responsible for the psychoactive effects of these fungi [131].
Mushrooms can be eaten after drying and making tea, but the most common route of con-
sumption is by eating whole mushroom capsules [92]. After being consumed, psilocybin is
converted into psilocin, and it acts as an agonist for the serotonergic receptors 5-HT1a and
5-HT2a, exerting its psychoactive effects [79]. In addition, these compounds can also in-
crease the release of glutamate, which activates receptors such as N-methyl-d-aspartic acid
receptors and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors [50,132].
The effects caused when consuming magic mushrooms can also be partially and indirectly
mediated by dopamine [133].
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12. Salvia divinorum (“Hierba de Maria”) 
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Figure 10. Psilocybe mushrooms (A) and the main compounds psilocybin (B) and psilocin (C).
The effects of Psilocybe consumption include changes in perception similar to drugs
such as LSD, namely changes in visual and auditory perception [3]. Mystical experiences,
tachycardia, headache, sweating, mydriasis, chills, nausea and increased body temperature
are also associated with the consumption of magic mushrooms [134,135]. Other effects
reported when consuming these substances are paranoia, dizziness and imbalance and
abdominal pain, [79,135]. Moreover, it has been reported that psilocybin can be used to
treat anxiety and resistant depression [136].
Psilocybe mushrooms are illegal all over the world [137]. However, in some countries,
the law is ot conse sual, namely in the Netherlands where the mushroom is illegal, but the
Sclerotia truffle (philosopher’s stone) is ot [3]. Given the worldwide consumption of this
substance, the development of new analytic l methods that all w the determination of
these compou ds is crucial (Table 7). S veral samples were used to quan ify the active com-
pounds of Psilocybe, namely urin [91,138], serum [139] and h ir [67]. Kamata et al. [139]
d veloped a method for the quantification of psilocin glucuronid , where they us
only 100 µL of serum. The sample was subjected to an enzymatic hydrolysis and d -
proteinization proc ss, after which it was injected into LC-MS a d LC-MS/MS equipment.
The method showed 0.5 ng/mL LOD. The same uthors had previously developed an ana-
lytical method for t e quantification of psiloc n glucuronide a d psilocin, wher they used
the same volume of urin and the same equipment, a d the same LOD was obtained [138].
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Table 7. Analytical methods for the determination of the main components of the Psilocybe genus.
















































0.01–0.02 µg/g 0.03–0.05 µg/g 79.6–97.4 [67]
Caption: ESI (electrospray ionization); LC (liquid chromatography); MS (mass spectrometry); MS/MS (tandem mass spectrometry);
UHPLC (ultrahigh-performance liquid chromatography).
12. Salvia divinorum (“Hierba de Maria”)
S. divinorum (Figure 11A) originates from Oaxaca, a region in the northeast of the
Sierra Mazateca, Mexico [140]. This psychoactive plant, also known as hierba de Maria,
hojas de la Pastora, ska Maria, ska Pastora and magic mint, has been used for centuries by
indigenous people because they believe it is the reincarnation of the Virgin Mary [12,141].
S. divinorum is consumed by chewing fresh or dried leaves. Dried leaves can be also smoked,
and fresh leaves can be used to make tea [3]. The main psychoactive constituent of this plant
is salvinorin A (Figure 11B), but other compounds were also detected, such as salvinorins
B (Figure 11C), C, D, E and F, but these do not have pharmacological activity [3,12].
Salvinorin A acts as a selective agonist for Kappa opioid receptors (KOR), thereby exerting
its potent hallucinogenic effects [12,142]. A dose of between 200 µg and 500 µg is capable
of inducing deep hallucinations with extraordinary illusions and a feeling of physical and
mental displacement [143,144]. However, some studies conducted with S. divinorum and
its bioactive compound salvinorin A have shown that it has some effects with therapeutic
potential, such as drug addiction, pain treatment, neurological, gastrointestinal diseases
and anti-inflammatory agent [145–156].
Despite its high potency, this substance is not included in any of the United Nations
Drug Conventions’ Schedules [3]. However, in Denmark, Latvia, Belgium, Lithuania,
Sweden, Romania, Japan and Australia, these compounds are controlled. S. divinorum
is considered an illegal drug in the United States of America, and its sale in Canada is
also prohibited [3]. Other countries such as Germany, Poland, Croatia and Spain regu-
late its manufacture, and in Norway, Estonia and Finland this plant is legislated by the
legislation of medicines [3]. Together with the consumption of C. edulis and M. speciosa,
the consumption of S. divinorum is controlled by the United Nations Office on Drugs and
Crime (UNODC) [3].
The consumption of this substance has expanded worldwide and, therefore, sev-
eral analytical methodologies for the detection of salvinorin A have emerged (Table 8).
Thus, several biological samples have been used for the development of these analytical
methodologies, namely, urine [157–160], plasma [159,161], saliva [161], sweat [161], peri-
cardial fluid [161], vitreous humor [161], blood [161] and hair [67]. Margalho et al. [161]
quantified salvinorin A in pericardial fluid, vitreous humor, blood and plasma in the same
analytical method. The quantity of the samples was reduced (100 µL-250 µL), being treated
using the SPE technique [161]. Finally, the compounds were quantified using GC-MS
equipment, and the method proved to be sensitive and selective, presenting LOD and LOQ
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of 5 ng/mg [161]. Moreno et al. [160] quantified salvinorin A in urine samples (200 µL)
using MEPS as the sample pre-treatment technique. The samples were analyzed by GC-
MS/MS equipment, with good recoveries (71%–80%) and good LOD and LOQ (5 ng/mL
and 20 ng/mL, respectively) [160].




Figure 11. S. divinorum (A) and the main compounds salvinorin A (B) and salvinorin B (C). 
13. Tabernanthe iboga (Iboga) 
T. iboga (Figure 12A) is a shrub from Central and West Africa [94,162]. This plant has 
been consumed for centuries in religious rituals of initiation into adulthood (Bwiti reli-
gion) in countries located in Central Africa and in the Congo basin [94,163]. The root 
barks of T. iboga contain psychoactive alkaloids, the majority of which are called ibogaine 
(Figure 12B) [162]. This compound, which consists of a monoterpene-indole alkaloid, is 
consumed orally in the form of hydrochloride, extracts of alkaloids or by consumption of 
the dry root bark [162,164,165]. When consuming, users experience stimulating and 
aphrodisiac properties, trance, energization and increased alertness [94,163]. The con-
sumption of this substance also causes hallucinations that, in contrast to common hallu-
cinogens, are more intense and realistic when experienced with closed eyes [162]. Despite 
the structure of ibogaine being similar to other hallucinogens, this compound has a dif-
ferent mode of action [162]. So far, its mechanism of action is not fully known, but it is 
known that it is able to act as an agonist of σ2 receptors and an antagonist of nicotinic 
α3β4 acetylcholine receptors and as an antagonist at N-methyl-d-aspartatetype (NMDA) 
glutamate receptors [164,165]. 
Throughout history, the extract of T. iboga has been used for other purposes, namely 
for fatigue and depression [166]. Currently, ibogaine is used in opioid detoxification 
[94,162]. Thus, this compound is legal in most countries, however, in Switzerland, Bel-
gium, Australia, Sweden, France, Denmark and the United States of America, it is illegal 
[162]. Currently, there are several methodologies for quantifying T. iboga compounds, 
namely using biological samples such as plasma [167], urine [88,91], blood [89] and se-
rum [88]. Pietsch et al. [88] developed an analytical method where they determined, 
among other compounds, ibogaine. For this, they used HPLC-PDA and HPLC-UV 
equipment, using 1 mL of serum and 1 mL of urine, which were pre-treated with SPE 
[88]. Furthermore, Björnstad et al. [91] developed an analytical method where they 
quantified ibogaine and other compounds. This analytical method had a LOD between 2 
ng/mL and 10 ng/mL and presented a very easy sample preparation technique [91]. Only 
50 µL of urine were used, which were diluted and injected directly into LC-MS/MS 
equipment [91]. 
Figure 11. S. divinorum (A) and the main compounds salvinorin A (B) and salvinorin B (C).
Table 8. Analytical m thods for the determin tion of the main components of Salvia divinorum.
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GC-MS (EI) 5.0 µg/L 5.0 µg/L - [161]
Salvinorin A Urine (0.2 mL) MEPS (C18)
GC-MS/MS
(EI) 5.0 µg/L 20 µg/L 71–80 [160]
Caption: EI (electron impact); ESI (electrospray ionization); GC (gas chromatography); GC × GC (bidimensional gas chromatogra-
phy); LC (liquid chromatography); LLE (liquid-liquid extraction); MEPS (microextraction by packed sorbent); MS (mass spectrometry);
MS/MS (tandem mass spectrometry); SPE (solid-phase extraction); ToF (time of flight).
13. Tabernanthe iboga (Iboga)
T. iboga (Figure 12A) is a shrub from Central nd West Africa [94,162]. This plant
has been consumed for centuries in religious rituals of initiation into adulthood (Bwiti re-
ligion) in countries located in Central Africa and in the Congo basin [94,163]. The root
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barks of T. iboga contain psychoactive alkaloids, the majority of which are called ibogaine
(Figure 12B) [162]. This compound, which consists of a monoterpene-indole alkaloid,
is consumed orally in the form of hydrochloride, extracts of alkaloids or by consumption
of the dry root bark [162,164,165]. When consuming, users experience stimulating and
aphrodisiac properties, trance, energization and increased alertness [94,163]. The consump-
tion of this substance also causes hallucinations that, in contrast to common hallucinogens,
are more intense and realistic when experienced with closed eyes [162]. Despite the struc-
ture of ibogaine being similar to other hallucinogens, this compound has a different mode
of action [162]. So far, its mechanism of action is not fully known, but it is known that
it is able to act as an agonist of σ2 receptors and an antagonist of nicotinic α3β4 acetyl-
choline receptors and as an antagonist at N-methyl-d-aspartatetype (NMDA) glutamate
receptors [164,165].




Figure 12. Tabernanthe iboga (A) and the main compound ibogaine (B). 
14. Conclusions 
Throughout this review, several plants/fungi that have psychoactive substances 
capable of inducing relaxing, stimulating or hallucinogenic effects were addressed. Tox-
icological aspects, some therapeutic properties and traditional uses were highlighted, as 
well as some of the analytical methods, developed in biological matrices, aimed at the 
detection of these substances. 
Given the rapid emergence of these psychoactive substances in the abused drugs 
market, as well as the lack of legislation to control them, the development of new ana-
lytical methodologies is crucial. However, the lack of analytical standards to proceed 
with the development of chromatographic methods or the difficulty in finding plant 
specimens that allow scans of the compounds present in them constitute an enormous 
difficulty. Additionally, the fact that the compounds are usually present in very small 
amounts makes it even more difficult to develop and validate new methodologies, re-
quiring the use of more sophisticated equipment, such as mass spectrometry detectors. 
Finally, the fact that the matrices of plant origin have several interferents also constitutes 
a difficulty, since it is necessary to apply a pre-treatment step to the sample. This proce-
dure makes the development of methods more expensive and requires the use of organic 
solvents. In the future, the use of miniaturized extraction techniques should be priori-
tized in order to achieve the development of more economical methods that aim to use 
lower volumes of organic solvents and, consequently, be more environment-friendly. 
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Figure 12. Tabernanthe iboga (A) and the main compound ibogaine (B).
Throughout history, the extract of T. iboga has been used for other purposes, namely for
fatigue and depression [166]. Currently, ibogaine is used in opioid detoxification [94,162].
Thus, this compound is legal in most cou tries, however, in Switzerl nd, Belgium, Aus-
tralia, Sweden, France, Denmark nd the United States of America, it is illegal [162].
Currently, th re are several methodologies for quan ifying T. iboga compounds, namely us-
ing biol gical samples su h as plasma [167], urine [88,91], blood [89] and s rum [88].
Pi tsch et al. [88] develop d an analytical method where they determined, among other
compou ds, ibogaine. For this, they used HPLC-PDA and HPLC-UV eq ipment, us-
ing 1 mL of serum and 1 mL of urine, which we e pre-trea ed with SPE [88]. Furthermore,
Björnstad et al. [91] developed an analytical method where they qu tifie ib gaine and
o er compounds. This analytic l method had a LOD between 2 ng/mL a 10 ng/mL
and pre ented a very e sy sample pre aration tech ique [91]. Only 50 µL of urine were
used, which were diluted and injected directly into LC-MS/MS equipment [91].
14. Conclusions
Throughout this review, several plants/fungi that have psychoactive substa ces capa-
ble of inducing relaxing, stimulating or hallucinogenic effects were addressed. Toxicological
aspects, some therapeutic properties and traditional uses were highlighted, as well as some
of the analytical methods, developed in biological matrices, aimed at the detection of
these substances.
Given the rapid emergence of these psychoactive substances in the abused drugs
market, as well as the lack of legislation to control them, the development of new analytical
methodologies is crucial. However, the lack of analytical standards to proceed with the
d velopment of chromatogr phic meth ds or the difficulty in finding plant specimens
that allow scans of the compounds present in them con titute an enormous difficulty.
Additionally, the fact that the compounds are usually present in very small amounts makes
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it even more difficult to develop and validate new methodologies, requiring the use of
more sophisticated equipment, such as mass spectrometry detectors. Finally, the fact
that the matrices of plant origin have several interferents also constitutes a difficulty,
since it is necessary to apply a pre-treatment step to the sample. This procedure makes
the development of methods more expensive and requires the use of organic solvents.
In the future, the use of miniaturized extraction techniques should be prioritized in order
to achieve the development of more economical methods that aim to use lower volumes of
organic solvents and, consequently, be more environment-friendly.
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162. Alper, K.R.; Stajić, M.; Gill, J.R. Fatalities Temporally Associated with the Ingestion of Ibogaine. J. Forensic Sci. 2012, 57, 398–412. [CrossRef]
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